(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenoxypent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide

Prostaglandin F_2α (PGF_2α), acting through the FP receptor, causes smooth muscle contraction and exhibits potent luteolytic activity. Both 17-phenyl trinor PGF_2α and 16-phenoxy tetranor PGF_2α are metabolically stable analogs of PGF_2α and potent agonists for the FP receptor. 17-phenoxy trinor PGF_2α ethyl amide is a lipophilic analog of 17-phenoxy trinor PGF_2α . Ethyl amides of PGs serve as prodrugs, as they are hydrolyzed in certain tissues to generate the bioactive free acid.

17-Phenoxy trinor prostaglandin F2α ethyl amide (17-Phenoxy trinor PGF2α ethyl amide) is an analog of Bimatoprost (HY-12956). 17-Phenoxy trinor prostaglandin F2α ethyl amide is an agonist for Prostaglandin F2α Receptor (FP receptor). 17-Phenoxy trinor prostaglandin F2α ethyl amide is potent to reduce the intraocular pressure and attenuate the glaucoma[1][2].

[1] Balapure AK, et al., Structural requirements for prostaglandin analog interaction with the ovine corpus luteum prostaglandin F2 alpha receptor. Implications for development of a photoaffinity probe. Biochem Pharmacol. 1989 Jul 15;38(14):2375-81. DOI:10.1016/0006-2952(89)90478-4
[2] Woodward DF, et al., Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024). J Pharmacol Exp Ther. 2003 May;305(2):772-85. DOI:10.1124/jpet.102.047837